CL2008000987A1 - Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina; procedimiento de preparacion, util para tratar enfermedades mediadas por rage, tales como alzheimer, cancer, inflamacion aguda y cronica, - Google Patents

Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina; procedimiento de preparacion, util para tratar enfermedades mediadas por rage, tales como alzheimer, cancer, inflamacion aguda y cronica,

Info

Publication number
CL2008000987A1
CL2008000987A1 CL200800987A CL2008000987A CL2008000987A1 CL 2008000987 A1 CL2008000987 A1 CL 2008000987A1 CL 200800987 A CL200800987 A CL 200800987A CL 2008000987 A CL2008000987 A CL 2008000987A CL 2008000987 A1 CL2008000987 A1 CL 2008000987A1
Authority
CL
Chile
Prior art keywords
penoxi
dietil
propil
butil
amina
Prior art date
Application number
CL200800987A
Other languages
English (en)
Spanish (es)
Inventor
Hari Anitha
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of CL2008000987A1 publication Critical patent/CL2008000987A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
CL200800987A 2007-04-05 2008-04-04 Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina; procedimiento de preparacion, util para tratar enfermedades mediadas por rage, tales como alzheimer, cancer, inflamacion aguda y cronica, CL2008000987A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92196407P 2007-04-05 2007-04-05
US92578607P 2007-04-23 2007-04-23

Publications (1)

Publication Number Publication Date
CL2008000987A1 true CL2008000987A1 (es) 2008-08-08

Family

ID=39469930

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800987A CL2008000987A1 (es) 2007-04-05 2008-04-04 Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina; procedimiento de preparacion, util para tratar enfermedades mediadas por rage, tales como alzheimer, cancer, inflamacion aguda y cronica,

Country Status (11)

Country Link
US (2) US7884219B2 (OSRAM)
EP (1) EP2144883A1 (OSRAM)
JP (1) JP2010523559A (OSRAM)
AR (1) AR065896A1 (OSRAM)
CA (1) CA2681864A1 (OSRAM)
CL (1) CL2008000987A1 (OSRAM)
PA (1) PA8775601A1 (OSRAM)
PE (1) PE20090808A1 (OSRAM)
TW (1) TW200900384A (OSRAM)
UY (1) UY31004A1 (OSRAM)
WO (1) WO2008123914A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681864A1 (en) * 2007-04-05 2008-10-16 Transtech Pharma, Inc. Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
US9717710B2 (en) * 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
AU2013327450B2 (en) * 2012-10-05 2018-07-12 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
CN103726005A (zh) * 2012-10-16 2014-04-16 深圳富泰宏精密工业有限公司 珐琅涂层的制造方法及其制品
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
JP7464591B2 (ja) * 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー ［３－（４－｛２－ブチル－１－［４－（４－クロロ－フェノキシ）－フェニル］－１ｈ－イミダゾール－４－イル｝－フェノキシ）－プロピル］－ジエチル－アミンの代謝産物
WO2020086388A1 (en) 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
US11648235B1 (en) 2022-12-30 2023-05-16 Cantex Pharmaceuticals, Inc. Treatment of glioblastoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1482931B1 (en) * 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
CN1805743A (zh) 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
CA2681864A1 (en) * 2007-04-05 2008-10-16 Transtech Pharma, Inc. Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine

Also Published As

Publication number Publication date
TW200900384A (en) 2009-01-01
EP2144883A1 (en) 2010-01-20
US20110166361A1 (en) 2011-07-07
UY31004A1 (es) 2008-11-28
US20080249316A1 (en) 2008-10-09
PE20090808A1 (es) 2009-06-27
US7884219B2 (en) 2011-02-08
CA2681864A1 (en) 2008-10-16
US8372988B2 (en) 2013-02-12
PA8775601A1 (es) 2009-04-23
WO2008123914A1 (en) 2008-10-16
JP2010523559A (ja) 2010-07-15
AR065896A1 (es) 2009-07-08

Similar Documents

Publication Publication Date Title
CO6920258A2 (es) Proteínas de función dual para tratar trastornos metabólicos
EP2768514A4 (en) LOCALIZED MODULATION OF TISSUES AND CELLS TO IMPROVE THERAPEUTIC EFFECTS INCLUDING RENAL RECURRING
WO2013151668A3 (en) Modified polynucleotides for the production of secreted proteins
HK1206612A1 (en) Modified polynucleotides for the production of secreted proteins
BR112012002578A2 (pt) composição para o tratamento da fibrose cística
DK2510150T3 (da) Hidtil ukendt fremgangsmåde til behandling af lignocelluloseholdigt materiale
CO6920257A2 (es) Protéinas de fusión para tratar trastornos metabólicos
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
BRPI1009281A2 (pt) composição oftálmica tópica
BR112014011009A2 (pt) inibidor duplo de met e vegf para tratar câncer
ITTO20110627A1 (it) Composizione farmaceutica di combinazione e metodi per trattare diabete e patologie metaboliche
BRPI0914614A2 (pt) 2-arilaminoquinazolinas para tratar doenças proliferativas
BR112013017669A2 (pt) di-hidrofuranos fundidos como moduladores de gpr119 para o tratamento de diabetes, obesidade e doenças relacionadas
IL228090A0 (en) Compositions and methods for personal tumor profiling treatment
BRPI0919327A2 (pt) compostos ligados a enxofre para tratar doenças e distúrbios oftálmicos
IL228771A0 (en) Glycoside derivatives and their uses for the treatment of diabetes
BRPI1005380A2 (pt) colírio com difluprednato para tratar edema macular, e uso de difluprednato para produzir o dito colírio
BR302013001867S1 (pt) Configuração aplicada em aparelho para reprodução de sons
CL2007003194A1 (es) Formas cristalinas del hemi fumarato de alisquireno; procedimiento de preparacion; composicion farmaceutica que comprende a dichas formas cristalinas; y su uso para tratar enfermedades que se modulan con bloqueo del receptor at1, tales como regulacio
EP3094956A4 (en) Preparation of cells, cell aggregates, and tissue fragments
EP2247297A4 (en) THERAPEUTIC TREATMENT OF LUNG DISEASES
BR112012006437A2 (pt) composições e métodos para tratamento do diabetes e outros distúrbios
BR112012015386A2 (pt) composição oftálmica tópica
BR112014015513A2 (pt) composição para aplicação tópica, processo cosmético para tratar uma matéria queratínica e uso de uma composição cosmética
BR112012002353A2 (pt) uso de inibidores nkg2d para tratamento de doenças cardiovasculares e metabólicas, tal como diabetes do tipo 2